ARTICLE | Deals
Like a ROCK: Sanofi takes out Kadmon for $1.9B, gains transplant drug
Takeout of the Waksal-led biotech comes on the heels of the approval of the company’s ROCK2 inhibitor for GvHD
September 8, 2021 8:23 PM UTC
Updated on Sep 17, 2021 at 8:17 PM UTC
Kadmon’s decade-long commitment to developing ROCK inhibitors has culminated in a $1.9 billion takeout by Sanofi, less than two months after the biotech’s first drug approval.
The deal gives Sanofi (Euronext:SAN; NASDAQ:SNY) Rezurock belumosudil, a ROCK2 inhibitor that gained FDA’s approval on July 16 for chronic graft-versus-host disease (GvHD). Kadmon Holdings Inc. (NASDAQ:KDMN) launched Rezurock last month, and has yet to report initial sales...